Editor's ESMO 2016 roundup

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

Drug repurposing of propranolol

ESMO 2016 conference highlights

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Olaparib and paclitaxel for 2nd line gastric cancer therapy

Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate

Highlights of ESMO 2016

Benefits of adjuvant chemo for soft tissue sarcoma patients

Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma

Negative trial results of custirsen for metastatic prostate cancer